What the Trial Data Actually Tell Us The STEP-3 trial paired semaglutide 2.4 mg with a structured lifestyle intervention: a calorie target, behavioral counseling, and 30 minutes of daily physical activity
Retatrutide at the 12 mg dose with 24.2% over 48 weeks (TRIUMPH-1, NEJM 2023), followed by tirzepatide at 15 mg with 20.9% over 72 weeks (SURMOUNT-1), then semaglutide at 2.4 mg with 14.9% over 68 weeks (STEP-1)
Ann Nutr Metab 43(1):2329
Cardiovascular disease in chronic renal insufficiency
The boxed thyroid tumor warning, rare pancreatitis, gallbladder disease, and other risks apply regardless of dose, and some are contraindications
At Cymbiotika, we believe that understanding the "how" and "why" behind your supplements is the first step toward building a routine you can trust